Australia's most trusted
source of pharma news
Wednesday, 18 March 2026
Posted 17 March 2026 PM
UCB's Bimzelx has officially surged into blockbuster status, with global sales booming from AU$1 billion in 2024 to $3.7 billion in 2025 - and the analyst consensus is that it will grow to around $5.04 billion this year.
The majority of the growth came from the US, where sales exploded from AU$466 million (287 million euros) to $2.6 billion (1657 million euros).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.